Scientific deep-dive

Retatrutide and kidney protection: Phase 2 post-hoc evidence and TRANSCEND-CKD

Retatrutide is investigational and not FDA-approved. Heerspink 2025 Kidney Int Rep post-hoc Phase 2: 12 mg cut UACR -37% at 36 wk in T2D; 8/12 mg raised eGFR +5.3/+8.5 mL/min/1.73 m2 in obesity at 48 wk. TRANSCEND-CKD Phase 2b (n=146) results not yet published.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
19 min read·14 citations

This evidence review is part of Weight Loss Rankings’ living editorial database — 1,180+ research articles and 640+ editorially reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.

Retatrutide is an Eli Lilly investigational triple agonist at the GIP, GLP-1, and glucagon receptors. It is NOT FDA-approved — for chronic kidney disease, type 2 diabetes, obesity, or any other indication — anywhere worldwide as of October 2026; Lilly plans to submit a Biologics License Application for obesity-related indications in Q1 2027[11]. The published human kidney evidence consists of one POST-HOC pooled analysis of two Phase 2 substudies (Heerspink 2025 Kidney Int Rep, PMID 40630318), and one design paper for the TRANSCEND-CKD Phase 2b mechanistic study (Heerspink 2026 Nephrol Dial Transplant, PMID 41160422; ClinicalTrials.gov NCT05936151), which ClinicalTrials.gov lists as completed but whose results have not been published. Two 2026 rodent studies add early mechanistic data, not human evidence[12][13]. The Phase 3 weight-loss trials TRIUMPH-1 (NEJM 2026) and TRIUMPH-2 (Lancet 2026) are now published, but their abstracts report no kidney endpoints[9][10]. The dedicated Phase 3 cardio-kidney outcomes trial TRIUMPH-Outcomes (NCT06383390) has not yet read out. This article walks through what the post-hoc analysis actually showed, what TRANSCEND-CKD is designed to test, and how the evidence compares to the FLOW (semaglutide), SELECT (semaglutide), and SURPASS-4 (tirzepatide) kidney data.

The honest answer

Retatrutide is investigational only. It is NOT FDA-approved for CKD (or any indication) anywhere worldwide as of October 2026. Heerspink 2025 Kidney Int Rep is a POST-HOC pooled analysis of Phase 2 substudies in baseline eGFR ≥45 patients — not a Phase 3 kidney outcomes trial. TRANSCEND-CKD Phase 2b mechanistic study finished in October 2025 (ClinicalTrials.gov) but has NOT yet published results: as of October 2026 there is no results paper on PubMed and no results posting on ClinicalTrials.gov. The only GLP-1-class agent with FDA-recognized kidney-protection labeling today is semaglutide (Ozempic), via the FLOW trial.

At a glance

  • Not FDA-approved. Retatrutide (LY3437943) is investigational only as of October 2026 — not approved for CKD, T2D, obesity, or any indication anywhere in the world. Lilly plans to submit a Biologics License Application in Q1 2027[11].
  • Heerspink 2025 Kidney Int Rep (PMID 40630318) is a post-hoc pooled analysis of two Phase 2 retatrutide studies (T2D n=281 and obesity-without-T2D n=338), baseline eGFR ≥45 mL/min/1.73 m2, most participants normoalbuminuric[1].
  • T2D 36-week results: retatrutide 12 mg reduced UACR by -37.0% (95% CI -57.3 to -7.0) vs placebo; eGFR was unchanged vs placebo[1].
  • Obesity 48-week results: retatrutide 8 mg / 12 mg reduced UACR by -28.0% / -31.5% and INCREASED creatinine-based eGFR by +5.3 / +8.5 mL/min/1.73 m2 vs placebo[1].
  • TRANSCEND-CKD (NCT05936151; PMID 41160422) is a Phase 2b mechanistic study, n=146 randomized, with Week 24 mGFR (iohexol clearance) as the primary endpoint, in adults with CKD (eGFR 25-75) with or without T2D[2].
  • TRIUMPH-Outcomes (NCT06383390) is the larger cardio-kidney outcomes trial cross-referenced in the TRANSCEND-CKD design paper; not yet read out[2].
  • Phase 3 weight-loss trials: TRIUMPH-1 (NEJM 2026; -25.0% body weight at 12 mg over 80 weeks) and TRIUMPH-2 (Lancet 2026; -18.8% at 12 mg in adults with type 2 diabetes) are published, but their abstracts report no kidney endpoints, so they do not change the kidney evidence summarized here[9][10].
  • FDA-approved comparators with kidney evidence: semaglutide (Ozempic) has the FLOW positive outcomes trial (HR 0.76) and an FDA CKD-progression label update[3]; tirzepatide has the SURPASS-4 post-hoc eGFR-slope analysis[5] and a 2026 exploratory SURPASS-CVOT kidney analysis (HR 0.77 vs dulaglutide)[14], but no dedicated kidney outcomes trial or kidney label.

What CKD is and why GLP-1 / triple agonism could matter

Chronic kidney disease (CKD) is the progressive loss of kidney function. The standard staging system uses two parameters: the estimated glomerular filtration rate (eGFR), which estimates how much plasma the kidneys filter per minute per 1.73 m2 of body-surface area, and the urinary albumin-to-creatinine ratio (UACR), which measures kidney-barrier leakiness. Stages 1-2 are mild (eGFR ≥60); stage 3a is 45-59; stage 3b is 30-44; stage 4 is 15-29; and stage 5 is <15 or dialysis-dependent. The two dominant CKD drivers worldwide are type 2 diabetes and hypertension, with obesity-related glomerular hyperfiltration increasingly recognized as a third independent driver.

The therapeutic goal in CKD is to slow the progression of eGFR decline and reduce hard outcomes — kidney failure (requiring dialysis or transplant), cardiovascular death, and all-cause mortality. The current FDA-approved pharmacologic pillars are renin-angiotensin system inhibitors (ACE inhibitors and angiotensin-receptor blockers), the mineralocorticoid-receptor antagonist finerenone (in diabetic kidney disease), and the SGLT2-inhibitor class (dapagliflozin and empagliflozin have CKD progression-reduction labeling).

The GLP-1 receptor agonist class joined this list in 2024 when the FDA approved a CKD progression-risk reduction indication for Ozempic (semaglutide) on the basis of the FLOW trial (Perkovic 2024 NEJM, PMID 38785209)[3]. For the FLOW deep-dive, see the FLOW trial and semaglutide kidney disease evidence. FLOW was the first positive kidney outcomes trial for any GLP-1-class agent and substantially changed how nephrologists frame the GLP-1 class.

The biological rationale for why the GLP-1 class could protect kidneys spans several plausible mechanisms: weight loss reduces obesity-driven glomerular hyperfiltration; glycemic control reduces hyperglycemia-driven tubular injury (in T2D); blood pressure reductions reduce mechanical stress on the glomerulus; and direct GLP-1 receptor signaling in the kidney appears to engage anti-inflammatory and natriuretic pathways. Retatrutide adds the GIP and glucagon receptor arms on top of GLP-1 agonism — whether this triple-class combination produces additive kidney protection or whether one of the arms (notably glucagon receptor agonism) could introduce off-target kidney effects is exactly what TRANSCEND-CKD is designed to evaluate.

What Heerspink 2025 Kidney Int Rep showed

Heerspink 2025 Kidney Int Rep (PMID 40630318) is the load-bearing published retatrutide kidney evidence as of October 2026[1]. Critically, it is a POST-HOC pooled analysis — not a prospective kidney outcomes trial.

Design and population:

  • Source studies. Pooled post-hoc analysis of two previously-conducted Phase 2 retatrutide trials — the T2D trial (Rosenstock 2023 Lancet, PMID 37385280) and the obesity-without-T2D trial (Jastreboff 2023 NEJM, PMID 37366315). Both source trials were placebo-controlled; the T2D trial additionally included dulaglutide 1.5 mg as an active comparator.
  • Sample sizes. T2D study n=281; obesity-without-T2D study n=338.
  • Baseline kidney function. Inclusion required eGFR ≥45 mL/min/1.73 m2. Mean creatinine-based eGFR was approximately 91 mL/min/1.73 m2 in the T2D study and 90 mL/min/1.73 m2 in the obesity study. Median baseline UACR was 13 mg/g (T2D) and 7 mg/g (obesity) — most participants were normoalbuminuric (UACR <30 mg/g).
  • Dose range. Retatrutide 0.5-12 mg weekly across ascending arms, plus placebo, plus the dulaglutide active comparator in the T2D study.
  • Follow-up. Change from baseline at Week 36 (T2D source study) and Week 48 (obesity source study).

T2D 36-week kidney results (retatrutide vs placebo):

  • UACR at retatrutide 12 mg: -37.0% (95% CI -57.3 to -7.0) vs placebo. Lower retatrutide doses were not specified as significantly different from placebo in the abstract.
  • eGFR at retatrutide 12 mg: unchanged compared with placebo.

Obesity-without-T2D 48-week kidney results (retatrutide vs placebo):

  • UACR at retatrutide 8 mg: -28.0% (95% CI -46.0 to -4.1) vs placebo.
  • UACR at retatrutide 12 mg: -31.5% (95% CI -49.3 to -7.4) vs placebo.
  • Creatinine-based eGFR at retatrutide 8 mg: +5.3 mL/min/1.73 m2 (95% CI 1.9-8.7) vs placebo.
  • Creatinine-based eGFR at retatrutide 12 mg: +8.5 mL/min/1.73 m2 (95% CI 4.9-12.1) vs placebo.
  • Cystatin-C-based and combined eGFR. Similar increases observed across these alternative eGFR estimators.

The authors’ verbatim conclusion: “Higher doses of retatrutide were associated with reduced UACR in participants with T2D and obesity, and with increased eGFR in participants with obesity but not in those with T2D.” The authors explicitly caveat that “because most patients had normal albuminuria, the absolute reduction in UACR was modest.”[1]

Important interpretive caveats:

  • Surrogate endpoints only. UACR and eGFR are surrogate markers, not hard kidney outcomes. The Phase 2 source studies were designed for glycemic and weight endpoints — not for kidney outcomes. The Heerspink kidney analysis is post-hoc.
  • Selected baseline kidney function. Inclusion required eGFR ≥45 — so CKD stages 3b, 4, and 5 are not represented. Patients with established CKD (the population FLOW enrolled for semaglutide) are largely not represented.
  • Normoalbuminuric population. Median baseline UACR was 7-13 mg/g — well below the macroalbuminuria threshold of 300 mg/g that FLOW enrolled. Percent changes from a near-normal baseline translate into very small absolute changes in albumin excretion.
  • Discordant T2D vs obesity eGFR signal. The eGFR increase was observed only in the obesity arm — not in T2D. The mechanistic explanation is not specified in the abstract.
  • No BP data extracted. Blood pressure changes per arm were not extracted in the published abstract.

Magnitude comparison

Heerspink 2025 Kidney Int Rep — UACR percent change vs placebo at the maximum retatrutide doses in the T2D 36-week analysis and obesity-without-T2D 48-week analysis. Bars represent magnitude of UACR reduction (absolute percent). Most participants in both source studies were normoalbuminuric at baseline so the absolute reduction in albumin excretion was modest despite the large percentage change.[1]

  • Reta 12 mg vs placebo — T2D 36 wk37.0 % UACR reduction
    95% CI -57.3 to -7.0
  • Reta 12 mg vs placebo — obesity 48 wk31.5 % UACR reduction
    95% CI -49.3 to -7.4
  • Reta 8 mg vs placebo — obesity 48 wk28.0 % UACR reduction
    95% CI -46.0 to -4.1
Heerspink 2025 Kidney Int Rep — UACR percent change vs placebo at the maximum retatrutide doses in the T2D 36-week analysis and obesity-without-T2D 48-week analysis. Bars represent magnitude of UACR reduction (absolute percent). Most participants in both source studies were normoalbuminuric at baseline so the absolute reduction in albumin excretion was modest despite the large percentage change.

TRANSCEND-CKD: what the Phase 2b mechanistic study is testing

TRANSCEND-CKD (ClinicalTrials.gov NCT05936151) is the dedicated retatrutide-in-CKD mechanistic trial. The design paper is Heerspink 2026 Nephrol Dial Transplant (PMID 41160422)[2].

Design and population:

  • Trial design. Double-blind, placebo-controlled, Phase 2b mechanistic study. Adults with overweight or obesity and chronic kidney disease.
  • Population. Adults with eGFR 25-75 mL/min/1.73 m2, with or without T2D. 37.7% of participants had T2D (HbA1c 7.1% SD 1.1%); non-T2D participants had HbA1c 5.7% (SD 0.3%).
  • Randomization. 367 screened, 146 randomized 1:1 to once-weekly retatrutide titrated to maximum tolerated dose up to 12 mg, or matched placebo.
  • Baseline characteristics. Mean age 65.1 years (SD 10.6), 45.2% female, 69.9% White, mean weight 101.1 kg (SD 20.6), mean BMI 35.7 kg/m2 (SD 6.1).
  • Baseline kidney function. Mean measured GFR (mGFR) 49.3 mL/min/1.73 m2 (SD 19.0); cystatin-C-based eGFR 49.6 mL/min/1.73 m2 (SD 13.2); creatinine-based eGFR 64.2 mL/min/1.73 m2 (SD 17.8); median baseline UACR 14.0 mg/g (IQR 6.0-69.0). 21.8% of participants were on SGLT2 inhibitors at baseline.
  • Primary objective. Change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 24.
  • Additional objectives. MRI-assessed kidney hemodynamic and volumetric measurements, including perirenal and renal sinus fat.
  • Treatment duration. Primary endpoint at Week 24.
  • Estimated primary-completion date. Not specified in the published abstract — consult the ClinicalTrials.gov NCT05936151 listing for the current estimated completion date.

Two important design features distinguish TRANSCEND-CKD from prior retatrutide kidney data:

  1. Measured GFR (mGFR) by iohexol clearance is the gold-standard direct measurement of glomerular filtration. It is more accurate than the creatinine- or cystatin-C-based estimating equations used in routine practice. Surrogate endpoints based on estimated GFR can be confounded by changes in muscle mass and tubular handling; iohexol clearance avoids those confounders.
  2. CKD-enriched population. Mean baseline mGFR was 49.3 mL/min/1.73 m2 (corresponding to roughly CKD stage 3a) with inclusion down to eGFR 25 (stage 4). This is substantially more impaired than the Heerspink 2025 post-hoc population (baseline eGFR ≥45, mean ≈90).

TRANSCEND-CKD will be a mechanistic readout, not a hard outcomes trial. The design paper explicitly cross-references TRIUMPH-Outcomes (NCT06383390) as the larger cardio-kidney outcomes trial that TRANSCEND-CKD is intended to inform[2]. TRIUMPH-Outcomes — if it reads out with a positive primary endpoint — would be the basis for any future FDA CKD label indication for retatrutide. As of May 25, 2026, neither trial has published primary results.

For the broader retatrutide regulatory and clinical-trial timeline, see retatrutide triple-agonist evidence review and retatrutide for type 2 diabetes evidence.

Cross-class context: FLOW (semaglutide in T2D + CKD)

FLOW (Perkovic 2024 NEJM, PMID 38785209) is the load-bearing positive kidney outcomes trial for the GLP-1 receptor agonist class[3]. Design and headline results:

  • ClinicalTrials.gov NCT03819153.
  • Population. Adults with T2D and CKD, defined as eGFR 50-75 mL/min/1.73 m2 with UACR 300-5000, OR eGFR 25 to <50 with UACR 100-5000. n=3,533 randomized (1,767 semaglutide, 1,766 placebo).
  • Intervention. Subcutaneous semaglutide 1.0 mg weekly vs placebo, on a background of standard kidney-protective care.
  • Median follow-up. 3.4 years — trial stopped early at a prespecified interim analysis after the predetermined number of primary events accumulated.
  • Primary composite outcome (kidney failure, sustained ≥50% eGFR reduction, kidney death, or CV death): 331 events in the semaglutide group vs 410 events in the placebo group. Hazard ratio 0.76 (95% CI 0.66-0.88, P=0.0003) — a 24% relative risk reduction.
  • eGFR slope. Annual eGFR decline was 1.16 mL/min/1.73 m2 slower in the semaglutide group (P<0.001).

FLOW supported an FDA label update for Ozempic to include reduction in the risk of CKD progression in adults with T2D and CKD. That makes Ozempic injection the only GLP-1-class product with an explicit FDA-recognized kidney-protection indication as of October 2026 (current Mounjaro, Zepbound, Wegovy, Rybelsus, Trulicity, and Victoza labels on DailyMed carry none). For the FLOW deep-dive, see the FLOW trial and semaglutide kidney disease evidence.

The interpretive bottom line for retatrutide vs FLOW: FLOW used hard kidney outcomes (kidney failure, ≥50% eGFR loss, kidney death) in a CKD-enriched, macroalbuminuric population over 3.4 years. The Heerspink 2025 retatrutide post-hoc used surrogate UACR and eGFR changes over 36-48 weeks in a non-CKD, mostly normoalbuminuric population. These are not comparable evidence bases. Retatrutide has no analogous outcomes-trial evidence today — TRIUMPH-Outcomes is the trial that, if positive, would generate it.

Cross-class context: SELECT renal subgroup (semaglutide in obesity)

SELECT renal subgroup (Colhoun 2024 Nat Med, PMID 38796653) is the dedicated kidney-outcomes analysis from the SELECT cardiovascular outcomes trial in adults with obesity and established CV disease[4]. The parent CV-outcomes paper is Lincoff PMID 37952131 (not cited here for kidney-specific data).

  • ClinicalTrials.gov NCT03574597.
  • Pre-specified main composite kidney endpoint: death from kidney disease, initiation of chronic kidney replacement therapy, persistent eGFR <15 mL/min/1.73 m2, persistent ≥50% eGFR reduction, or persistent macroalbuminuria.
  • Result: 1.8% semaglutide vs 2.2% placebo, HR 0.78 (95% CI 0.63-0.96, P=0.02).
  • eGFR treatment benefit at 104 weeks: 0.75 mL/min/1.73 m2 (95% CI 0.43-1.06, P<0.001) overall; 2.19 mL/min/1.73 m2 (95% CI 1.00-3.38, P<0.001) in the baseline eGFR <60 subgroup.

SELECT extends the GLP-1-class kidney signal into the obesity population without T2D — an arguably closer population to the Heerspink 2025 obesity arm than FLOW’s T2D + CKD population. The hazard ratio (0.78) for the SELECT renal composite is similar to FLOW’s 0.76 for the T2D + CKD primary composite. Both establish that the semaglutide kidney signal is reproducible across distinct populations. Retatrutide does not yet have comparable hard-outcomes data.

Cross-class context: SURPASS-4 (tirzepatide renal substudy)

SURPASS-4 renal substudy (Heerspink 2022 Lancet Diabetes Endocrinol, PMID 36152639) is the closest tirzepatide-class kidney data point[5].

  • ClinicalTrials.gov NCT03730662.
  • Population. Adults with T2D treated with metformin, sulfonylurea, or SGLT2 inhibitor; HbA1c 7.5-10.5%; BMI ≥25; established CV disease or high CV risk. n=2,002 randomized (997 tirzepatide pooled, 1,005 insulin glargine).
  • Baseline. Mean eGFR 81.3 (SD 21.11) mL/min/1.73 m2; median UACR 15.0 mg/g (IQR 5.0-55.8). Median treatment duration 85 weeks (up to 104 weeks).
  • eGFR slope result. Mean annual eGFR decline -1.4 (SE 0.2) mL/min/1.73 m2/yr in pooled tirzepatide arms vs -3.6 (SE 0.2) mL/min/1.73 m2/yr in insulin glargine — between-group difference 2.2 mL/min/1.73 m2/yr (95% CI 1.6-2.8).

Important caveats: SURPASS-4 is a post-hoc kidney analysis of an open-label trial whose primary endpoint was HbA1c, not kidney outcomes. The active comparator was insulin glargine, which has its own metabolic profile and is not a placebo. The eGFR-slope difference is suggestive of a tirzepatide kidney benefit but does not constitute a positive Phase 3 kidney outcomes trial.

A stronger tirzepatide kidney signal has since been published. Pre-specified exploratory analyses of SURPASS-CVOT (Zoungas 2026 Lancet Diabetes Endocrinol; 13,165 adults with T2D and atherosclerotic cardiovascular disease, median follow-up 4.0 years) found a 23% lower risk of a composite kidney outcome — persistent macroalbuminuria, ≥50% eGFR decline, end-stage kidney disease, or kidney death — with tirzepatide than with dulaglutide (HR 0.77, 95% CI 0.68–0.88), driven by fewer new cases of macroalbuminuria in people at low-to-moderate kidney risk and by slower eGFR decline in those at high risk[14]. That is a large randomized trial, but the kidney outcome was exploratory and the comparator was another GLP-1 drug, so it is not a dedicated kidney outcomes trial like FLOW. As of October 2026, tirzepatide has no FDA-recognized kidney-protection indication.

For the cross-class context bottom line: semaglutide (FLOW + SELECT renal) has Phase 3 hard-outcomes evidence with an FDA label update; tirzepatide has post-hoc (SURPASS-4) and exploratory (SURPASS-CVOT) Phase 3 kidney evidence but no dedicated kidney outcomes trial; retatrutide (Heerspink 2025) has post-hoc Phase 2 surrogate evidence only. TRANSCEND-CKD and TRIUMPH-Outcomes are the trials that, if positive, would put retatrutide closer to the semaglutide position. Neither has published results yet.

Mechanism: how triple agonism could affect renal parameters

Retatrutide-specific kidney mechanism data are so far limited to animal studies. The original Coskun 2022 Cell Metab pharmacology paper (PMID 35985340) characterizes receptor binding, signaling, and glycemic/weight effects but does not analyze the kidney[8]. Two 2026 rodent studies have since looked at the kidney directly. Ding 2026 (iScience) compared semaglutide, tirzepatide, and retatrutide in mouse models of non-diabetic renal fibrosis (unilateral ureteral obstruction and aging) and in human kidney cells; retatrutide’s effects were associated with inhibition of both the PI3K-AKT and NF-κB pathways, and it showed the greatest effect at the doses tested[12]. Keskin 2026 (J Mol Histol) gave retatrutide for 21 days to rats with streptozotocin-induced diabetes: renal HIF-1α expression was significantly lower than in untreated diabetic rats, but the tissue-damage scores did not show statistically confirmed protection, and the authors note that this acute, insulin-deficient model does not resemble type 2 diabetes[13]. These are hypothesis-generating animal data, not evidence of kidney protection in people. The mechanism discussion below is still largely INFERRED from the broader incretin literature.

Plausible mechanisms by which retatrutide could influence renal parameters:

  • Weight loss and reduction of obesity-related glomerular hyperfiltration. Phase 2 retatrutide produced 24% weight loss at 48 weeks at the 12 mg dose in the obesity trial (Jastreboff 2023, PMID 37366315)[6]. Weight loss reduces glomerular hyperfiltration and intraglomerular pressure — potentially explaining the +5.3 / +8.5 mL/min/1.73 m2 creatinine-eGFR increase observed in the obesity arm of Heerspink 2025. (Note: an isolated eGFR increase is not unambiguously beneficial — it could represent recovery from prior hyperfiltration OR could reflect changes in serum creatinine production driven by lean-mass changes.)
  • Glycemic control reducing tubular injury. In T2D, retatrutide produced HbA1c reductions up to -2.02% at 24 weeks in the Rosenstock 2023 Phase 2 trial (PMID 37385280)[7]. Improved glycemia reduces hyperglycemia-driven tubular toxicity, a plausible mediator of the T2D UACR reduction.
  • Blood pressure reduction. The GLP-1 class is known to produce modest BP reductions. The Heerspink 2025 abstract did NOT report BP changes per arm so this article cannot quote retatrutide-specific BP magnitudes. Full text of PMC12231004 may contain these data.
  • Direct GLP-1 receptor signaling in the kidney. GLP-1 receptors are expressed in renal proximal tubule and macula densa cells. GLP-1R signaling is associated with natriuresis, anti-inflammatory effects, and inhibition of oxidative-stress pathways in preclinical kidney models. Whether these effects scale to clinically meaningful kidney protection in humans treated with retatrutide is unknown.
  • Glucagon receptor agonism — theoretical risks and benefits. Glucagon receptor agonism could engage hepatic- renal axis pathways and increase energy expenditure, but in isolation could increase amino acid catabolism and urea load. The retatrutide-specific renal balance between GLP-1R benefit and any off-target glucagon-receptor effects is exactly what TRANSCEND-CKD’s direct mGFR measurement (iohexol clearance) and MRI hemodynamic measures are designed to characterize.

The honest mechanism summary: triple agonism plausibly engages multiple kidney-protective levers, and the first rodent studies point to anti-fibrotic and anti-inflammatory signaling in mice[12] and lower renal HIF-1α expression, without confirmed tissue protection, in diabetic rats[13], but there are no human mechanistic data yet. Mechanism remains hypothesis, not established fact, until TRANSCEND-CKD publishes its results.

What is not yet known about retatrutide and kidneys

  • Phase 3 hard kidney outcomes. No Phase 3 trial of retatrutide has read out with a primary kidney endpoint as of October 2026. TRIUMPH-Outcomes (NCT06383390) is the relevant trial; not yet published.
  • Hard endpoints — dialysis, transplant, kidney death. Heerspink 2025 measured UACR and eGFR, not hard outcomes. TRANSCEND-CKD measures mGFR by iohexol, also not a hard outcome. Whether retatrutide reduces dialysis, transplant, or kidney death is unknown.
  • CKD stages 3b, 4, 5. Heerspink 2025 required baseline eGFR ≥45 — so CKD stage 3b (eGFR 30-44), 4 (15-29), and 5 (<15 or dialysis-dependent) are not represented. TRANSCEND-CKD extends down to eGFR 25 but the sample size is small (n=146) and primary endpoint is Week 24 mGFR change, not outcomes.
  • Non-diabetic CKD. The retatrutide kidney evidence base is dominated by T2D (Rosenstock 2023 source) and obesity source studies. Non-T2D, non-obesity primary CKD etiologies (IgA nephropathy, polycystic kidney disease, glomerulonephritis, membranous nephropathy) have no retatrutide data.
  • Macroalbuminuric CKD. Most participants in the Heerspink 2025 source studies were normoalbuminuric (median UACR 7-13 mg/g). The macroalbuminuric population that FLOW enrolled (UACR >300) is not adequately represented.
  • Pediatric and post-transplant CKD. No data.
  • Long-term durability. Heerspink 2025 measured at 36 weeks (T2D) and 48 weeks (obesity). Whether UACR reductions and eGFR increases sustain over multi-year follow-up is unknown.
  • BP-mediated vs direct renal mechanism. Without per-arm BP data in the verified abstract, the contribution of BP changes to the observed UACR / eGFR signal cannot be quantified.

Practical takeaway for patients with CKD or kidney concerns

Retatrutide cannot be prescribed for CKD or for kidney protection today. Practical implications:

  • Retatrutide is investigational only. Not FDA-approved for any indication, anywhere worldwide, as of October 2026. Patients with CKD should NOT seek out compounded retatrutide for kidney protection — any source dispensing it is operating outside the FDA-regulated supply chain and the FDA has explicitly stated retatrutide may not lawfully be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. CKD adds additional patient-specific risk: reduced renal clearance can amplify the effects of contaminants, dose errors, or off-target ingredients in unverified compounded preparations. See retatrutide buy / regulatory sourcing evidence for the regulatory framing.
  • The FDA-approved GLP-1 with kidney-protection labeling is semaglutide (Ozempic). The FLOW trial (Perkovic 2024 NEJM) supported a CKD progression-risk reduction label update. For patients with T2D and CKD, this is the GLP-1-class option with the strongest FDA-recognized renal evidence today[3]. See the FLOW trial and semaglutide kidney disease evidence.
  • Tirzepatide does not have a positive Phase 3 kidney outcomes trial or an FDA renal-protection label as of October 2026. SURPASS-4 post-hoc data suggest slower eGFR decline vs insulin glargine, and exploratory SURPASS-CVOT analyses found fewer major kidney events than with dulaglutide[14], but neither is the same evidence standard as FLOW.
  • SGLT2 inhibitors (dapagliflozin, empagliflozin) remain a foundational kidney-protective class with FDA-recognized CKD-progression labeling. ACE inhibitors and angiotensin-receptor blockers remain the foundational RAAS-blockade class. Mineralocorticoid-receptor antagonists (finerenone) add an additional pillar in diabetic kidney disease.
  • For obesity-related glomerular hyperfiltration without T2D — the SELECT renal subgroup (semaglutide) is the closest published evidence base. The Heerspink 2025 retatrutide obesity-arm eGFR signal is intriguing but is a post-hoc Phase 2 surrogate endpoint, not a hard outcome.
  • If TRANSCEND-CKD reads out positively for mGFR improvement at Week 24, AND TRIUMPH-Outcomes reads out positively for hard cardio-kidney outcomes, AND FDA approves retatrutide for a CKD-related indication — then the practical positioning of retatrutide vs the existing kidney-protective pillars will need to be re-evaluated. Until those trials read out, retatrutide-for-CKD remains hypothesis only.
  • Defer to a licensed prescriber and a nephrologist for any CKD treatment decision. Patients with CKD have additional considerations — drug-clearance, RAAS-blockade interactions, electrolyte management — that require nephrology input.

Frequently Asked Questions

No. As of October 2026, retatrutide (Eli Lilly investigational compound LY3437943) is NOT FDA-approved for chronic kidney disease, for type 2 diabetes, for obesity, or for any other indication, anywhere worldwide. The published kidney-relevant data is limited to a post-hoc pooled analysis of two Phase 2 substudies (Heerspink 2025 Kidney Int Rep, PMID 40630318). The dedicated TRANSCEND-CKD Phase 2b mechanistic study (ClinicalTrials.gov NCT05936151) is listed as completed but has not published results. The cardio-kidney outcomes trial TRIUMPH-Outcomes (NCT06383390) has not yet read out. The only GLP-1-class agent with a positive kidney outcomes trial today is semaglutide via FLOW (Perkovic 2024 NEJM, PMID 38785209), which led to an FDA label update for Ozempic. CKD treatment decisions should be made with a licensed prescriber and ideally a nephrologist using FDA-approved options.
Heerspink 2025 (PMID 40630318) pooled kidney parameter data from two Phase 2 retatrutide studies — the T2D trial (n=281, Rosenstock 2023) and the obesity-without-T2D trial (n=338, Jastreboff 2023). All participants had baseline eGFR ≥45 mL/min/1.73 m2 and most had normal albuminuria (median UACR 13 mg/g in T2D, 7 mg/g in obesity). At the T2D 36-week endpoint, retatrutide 12 mg reduced UACR by -37.0% (95% CI -57.3 to -7.0) versus placebo; eGFR was unchanged versus placebo. At the obesity 48-week endpoint, retatrutide 8 mg and 12 mg reduced UACR by -28.0% (95% CI -46.0 to -4.1) and -31.5% (95% CI -49.3 to -7.4), and INCREASED eGFR by +5.3 mL/min/1.73 m2 (95% CI 1.9-8.7) and +8.5 mL/min/1.73 m2 (95% CI 4.9-12.1). Cystatin-C-based and combined eGFR showed similar increases. Because most participants were normoalbuminuric, the absolute UACR reduction was modest. This is a post-hoc Phase 2 substudy analysis, NOT a Phase 3 kidney outcomes trial.
TRANSCEND-CKD (ClinicalTrials.gov NCT05936151; design paper Heerspink 2026 Nephrol Dial Transplant, PMID 41160422) is a double-blind, placebo-controlled, Phase 2b mechanistic study in adults with overweight or obesity and chronic kidney disease (estimated GFR 25-75 mL/min/1.73 m2), with or without type 2 diabetes. 367 participants were screened and 146 were randomized 1:1 to once-weekly retatrutide titrated to maximum tolerated dose up to 12 mg versus matched placebo. The primary objective is change in measured glomerular filtration rate (mGFR) by iohexol clearance from baseline to Week 24. Additional objectives include MRI-assessed kidney hemodynamic and volumetric measurements, including perirenal and renal sinus fat. Baseline characteristics: mean age 65.1 years, 45.2% female, mean weight 101.1 kg, mean BMI 35.7. Mean baseline mGFR 49.3 mL/min/1.73 m2. 21.8% were on SGLT2 inhibitors at baseline. This is a mechanistic trial — not a kidney outcomes trial — and although ClinicalTrials.gov lists it as completed in October 2025, its primary readout has not yet been published on PubMed or posted on ClinicalTrials.gov as of October 2026.
TRIUMPH-Outcomes (ClinicalTrials.gov NCT06383390) is the larger cardio-kidney outcomes trial of retatrutide that Eli Lilly is running. The TRANSCEND-CKD design paper (Heerspink 2026 Nephrol Dial Transplant, PMID 41160422) explicitly cross-references TRIUMPH-Outcomes as the outcomes trial that TRANSCEND-CKD is intended to inform mechanistically. TRIUMPH-Outcomes will be the load-bearing trial for any future FDA kidney-protection labeling claim for retatrutide, analogous to how FLOW (NCT03819153) supported the Ozempic CKD label update for semaglutide. Neither TRANSCEND-CKD nor TRIUMPH-Outcomes has published primary results as of May 25, 2026. Any retatrutide-for-CKD prescribing decision today would be outside the FDA-approved indication framework.
Cross-trial comparison is not statistically valid — different populations, different durations, different endpoints. The reference points only: FLOW (Perkovic 2024 NEJM, PMID 38785209) randomized 3,533 adults with T2D and CKD (baseline eGFR 25-75 with albuminuria) to semaglutide 1.0 mg weekly vs placebo; primary composite kidney/CV outcome hazard ratio was 0.76 (95% CI 0.66-0.88, P=0.0003) over 3.4 years median follow-up. SELECT renal subgroup (Colhoun 2024 Nat Med, PMID 38796653) showed semaglutide reduced the pre-specified main composite kidney endpoint with HR 0.78 (95% CI 0.63-0.96, P=0.02) in adults with obesity and established CV disease. By contrast, the Heerspink 2025 retatrutide kidney paper is a post-hoc pooled analysis of two Phase 2 substudies measuring surrogate endpoints (UACR, eGFR) at 36-48 weeks — not hard outcomes. Until TRANSCEND-CKD and TRIUMPH-Outcomes publish, retatrutide has no FDA-recognized kidney-protection claim and no Phase 3 kidney outcomes evidence base. Defer to a prescriber.
The closest tirzepatide-class kidney data is SURPASS-4 (Heerspink 2022 Lancet Diabetes Endocrinol, PMID 36152639) — a post-hoc kidney analysis of an open-label Phase 3 trial. SURPASS-4 randomized 2,002 adults with T2D and high CV risk (mean baseline eGFR 81.3 mL/min/1.73 m2) to tirzepatide vs insulin glargine. The mean annual eGFR decline was -1.4 mL/min/1.73 m2/yr in pooled tirzepatide arms versus -3.6 mL/min/1.73 m2/yr in the insulin glargine arm, a between-group difference of 2.2 mL/min/1.73 m2/yr (95% CI 1.6-2.8). This is suggestive but is not a kidney outcomes trial with a hard primary endpoint. A stronger signal came in 2026 from pre-specified exploratory analyses of SURPASS-CVOT (Zoungas 2026, Lancet Diabetes Endocrinol, PMID 42114520): among 13,165 adults with T2D and atherosclerotic cardiovascular disease, tirzepatide lowered the risk of a composite kidney outcome by 23% versus dulaglutide (HR 0.77). Because the kidney outcome was exploratory, tirzepatide still has no dedicated positive kidney outcomes trial and no FDA kidney indication as of October 2026. The Ozempic FDA label update following FLOW remains the only GLP-1-class kidney-protection labeling indication.
No. Retatrutide is investigational only and there is no FDA-cleared retatrutide product. Any source selling “retatrutide” or “compounded retatrutide” is operating outside the FDA-regulated supply chain — FDA has reiterated that retatrutide is not approved for any indication, has no shortage status, and may not lawfully be compounded under section 503A of the Federal Food, Drug, and Cosmetic Act. Patients with CKD have additional risks: an unverified, non-FDA-supplied peptide could carry contaminants, impurities, or dose errors that would be particularly dangerous in reduced renal clearance. CKD patients seeking kidney protection should discuss FDA-approved options with a prescriber and a nephrologist. See our regulatory framing at /research/retatrutide-buy-regulatory-sourcing-evidence.
Retatrutide-specific kidney mechanism data so far come only from animals. In mouse models of non-diabetic renal fibrosis, retatrutide was associated with inhibition of the PI3K-AKT and NF-κB pathways (Ding 2026, iScience, PMID 42630988); in rats with streptozotocin-induced diabetes it lowered renal HIF-1α expression without statistically confirmed tissue protection (Keskin 2026, J Mol Histol, PMID 42878930). The original Coskun 2022 Cell Metab pharmacology paper (PMID 35985340) does not characterize renal-specific signaling. Inferring from the broader GLP-1 / incretin literature, plausible mechanisms include: (1) weight loss and reduction of obesity-related glomerular hyperfiltration; (2) glycemic control reducing hyperglycemia-driven tubular injury (in T2D); (3) blood pressure reduction (BP changes per arm were not extracted in the Heerspink 2025 abstract and are not cited in this article); (4) direct GLP-1 receptor signaling in renal proximal tubule and macula densa cells with anti-inflammatory and natriuretic effects; (5) glucagon receptor engagement of hepatic-renal axis pathways. Whether any of these translate into clinically meaningful, dose-dependent, sustained kidney protection in retatrutide-treated patients is exactly what TRANSCEND-CKD and TRIUMPH-Outcomes are designed to test. Until those trials publish, mechanism remains hypothesis, not established fact.
Several. The Heerspink 2025 Kidney Int Rep post-hoc analysis (PMID 40630318) explicitly excluded patients with eGFR <45 mL/min/1.73 m2 at baseline — so CKD stages 3b, 4, and 5 are not represented. Most participants were normoalbuminuric (median UACR 13 mg/g in T2D, 7 mg/g in obesity), so the macroalbuminuric population (the population FLOW enrolled for semaglutide) is underrepresented. Non-diabetic CKD without obesity is not addressed at all in published reta-kidney data. TRANSCEND-CKD does extend coverage down to eGFR 25, and includes both T2D and non-T2D participants, but the n=146 sample size is mechanistic-scale, not outcomes-scale. Patients with rapidly progressing CKD, dialysis-dependent CKD, post-transplant kidney function, or pediatric CKD have no retatrutide data. Defer to a nephrologist for any clinical decision in these populations.
Companion articles cover related angles. The retatrutide triple-agonist evidence review at /research/retatrutide-triple-agonist-evidence covers the broader Phase 2 obesity and T2D data, the mechanism, and the safety profile across indications. The retatrutide for type 2 diabetes evidence review at /research/retatrutide-for-type-2-diabetes-evidence covers the Phase 2 Rosenstock 2023 T2D trial in detail (one of the two source studies for the Heerspink 2025 kidney post-hoc). The FLOW trial deep-dive at /research/flow-trial-semaglutide-kidney-disease covers the semaglutide kidney outcomes evidence that supports the Ozempic CKD label. The retatrutide regulatory and sourcing review at /research/retatrutide-buy-regulatory-sourcing-evidence covers the FDA prohibition on compounded retatrutide. Treatment decisions should be made with a licensed prescriber and a nephrologist.
As a class, GLP-1 receptor agonists are generally regarded as kidney-neutral to kidney-protective, but the strongest FDA-recognized renal evidence today belongs to semaglutide: the dedicated FLOW kidney outcomes trial (Perkovic 2024 NEJM, PMID 38785209) supported an Ozempic label update for reducing CKD-progression risk in type 2 diabetes. Tirzepatide has suggestive post-hoc and exploratory data (SURPASS-4; SURPASS-CVOT) but no kidney-outcomes label, and retatrutide is investigational with no approved kidney indication — its renal effects are still being studied in TRANSCEND-CKD and TRIUMPH-Outcomes. For anyone with CKD, GLP-1 choice should be clinician-guided and layered onto foundational kidney-protective therapies such as SGLT2 inhibitors and RAAS blockade, because dosing, monitoring, and drug clearance all shift with reduced kidney function. Defer to a prescriber and a nephrologist for any individual decision.

Further reading

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.

Retatrutide (LY3437943) is an investigational compound. It is NOT FDA-approved for chronic kidney disease, type 2 diabetes, obesity, or any other indication, anywhere worldwide as of October 2026. Treatment decisions for CKD must be made with a licensed prescriber and ideally a nephrologist using FDA-approved medications. Every clinical claim in this article is anchored to a primary source. Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication or pharmacy.

References

  1. 1.Heerspink HJL, Sjöström CD, Inker LA, Hansen MK, Mosenzon O, Idorn T, Pratley R, Rasmussen S, Rossing P, Bakris G, Perkovic V. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Post-hoc pooled analysis of two Phase 2 retatrutide studies (T2D n=281; overweight/obesity without T2D n=338). Baseline eGFR ≥45 mL/min/1.73 m2. T2D 36-week: retatrutide 12 mg reduced UACR by -37.0% (95% CI -57.3 to -7.0) vs placebo; eGFR unchanged. Obesity 48-week: retatrutide 8 mg and 12 mg reduced UACR by -28.0% (95% CI -46.0 to -4.1) and -31.5% (95% CI -49.3 to -7.4); creatinine-based eGFR increased by +5.3 mL/min/1.73 m2 (95% CI 1.9-8.7) and +8.5 mL/min/1.73 m2 (95% CI 4.9-12.1). Cystatin-C-based and combined eGFR showed similar increases. Most patients were normoalbuminuric at baseline so absolute UACR reductions were modest. Kidney Int Rep. 2025. PMID: 40630318.
  2. 2.Heerspink HJL, Mosenzon O, Idorn T, Inker LA, Hansen MK, Sjöström CD, Pratley R, Rasmussen S, Rossing P, Bakris G, Perkovic V. Rationale, Design, and Baseline Characteristics of the TRANSCEND-CKD trial of Retatrutide in Patients with Chronic Kidney Disease. Double-blind, placebo-controlled, Phase 2b mechanistic study. ClinicalTrials.gov NCT05936151. 367 screened, 146 randomized 1:1 to once-weekly retatrutide titrated to maximum tolerated dose up to 12 mg vs placebo. Adults with overweight/obesity and CKD (eGFR 25-75 mL/min/1.73 m2), with or without T2D (37.7% T2D). Mean age 65.1 yr, 45.2% female, mean weight 101.1 kg, BMI 35.7. Mean baseline mGFR 49.3 mL/min/1.73 m2; cystatin-C eGFR 49.6; creatinine eGFR 64.2; median UACR 14.0 mg/g. 21.8% on SGLT2 inhibitors at baseline. PRIMARY OBJECTIVE: change in measured GFR (mGFR) by iohexol clearance from baseline to Week 24. Cross-references TRIUMPH-Outcomes (NCT06383390). Nephrol Dial Transplant. 2026. PMID: 41160422.
  3. 3.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R; FLOW Trial Committees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. FLOW trial. ClinicalTrials.gov NCT03819153. n=3,533 adults with T2D and CKD (eGFR 50-75 with UACR 300-5000, or eGFR 25 to <50 with UACR 100-5000) randomized to subcutaneous semaglutide 1.0 mg weekly vs placebo. Median follow-up 3.4 years; trial stopped early at prespecified interim. Primary composite kidney outcome (kidney failure, ≥50% sustained eGFR reduction, kidney or CV death): 331 vs 410 events, HR 0.76 (95% CI 0.66-0.88, P=0.0003). Annual eGFR slope difference 1.16 mL/min/1.73 m2 slower decline (P<0.001). FDA label updated to include CKD progression-risk reduction indication for Ozempic. N Engl J Med. 2024. PMID: 38785209.
  4. 4.Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. ClinicalTrials.gov NCT03574597. Pre-specified main composite kidney endpoint (death from kidney disease, chronic kidney replacement therapy, persistent eGFR <15, persistent ≥50% eGFR reduction, or persistent macroalbuminuria): 1.8% semaglutide vs 2.2% placebo, HR 0.78 (95% CI 0.63-0.96, P=0.02). eGFR treatment benefit at 104 weeks: 0.75 mL/min/1.73 m2 (95% CI 0.43-1.06, P<0.001) overall and 2.19 mL/min/1.73 m2 (95% CI 1.00-3.38, P<0.001) in baseline eGFR <60 subgroup. Dedicated SELECT renal subgroup paper; parent CV-outcomes paper is Lincoff PMID 37952131. Nat Med. 2024. PMID: 38796653.
  5. 5.Heerspink HJL, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, Wiese RJ, Tuttle KR, Cherney DZI. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. ClinicalTrials.gov NCT03730662. n=2,002 adults with T2D and high CV risk (mean baseline eGFR 81.3 mL/min/1.73 m2; median UACR 15.0 mg/g) randomized to tirzepatide pooled (997) vs insulin glargine (1,005). Median treatment 85 weeks. Mean annual eGFR decline: -1.4 (SE 0.2) mL/min/1.73 m2/yr tirzepatide vs -3.6 (SE 0.2) mL/min/1.73 m2/yr insulin — between-group difference 2.2 (95% CI 1.6-2.8) mL/min/1.73 m2/yr. Post-hoc kidney analysis — not a primary kidney outcomes trial. Lancet Diabetes Endocrinol. 2022. PMID: 36152639.
  6. 6.Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Parent Phase 2 obesity trial (n=338). One of the two source studies for the Heerspink 2025 post-hoc kidney analysis (obesity arm). Placebo-controlled; primary endpoint weight change at 24 and 48 weeks; retatrutide doses 1-12 mg weekly. N Engl J Med. 2023. PMID: 37366315.
  7. 7.Rosenstock J, Frias JP, Rodbard HW, Tofé S, Sears E, Huh R, Fernández Landó L, Patel H. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Parent Phase 2 T2D trial (n=281). One of the two source studies for the Heerspink 2025 post-hoc kidney analysis (T2D arm). Included dulaglutide 1.5 mg active comparator. Primary endpoint HbA1c at 24 weeks. ClinicalTrials.gov NCT04867785. Lancet. 2023. PMID: 37385280.
  8. 8.Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Original retatrutide pharmacology paper describing molecular design and the GIP-favored receptor activity ratio (R-GIPR > R-GLP-1R > R-GCGR). No kidney-specific mechanism analysis is presented in this paper. Cell Metab. 2022. PMID: 35985340.
  9. 9.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  10. 10.Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PMID: 42810372.
  11. 11.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
  12. 12.Ding M, Li X, Wei Y, Wang J, Jiao B, Li C, Ma W, Peng Y, Shen J, Yu G, Gao C. Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice. iScience. 2026. PMID: 42630988.
  13. 13.Keskin U, Altın E, Özatik FY, Sezgin AK, Gündoğdu AÇ, Arı NS, Kara MK. Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF-1α expression, and histopathological injury profile. J Mol Histol. 2026. PMID: 42878930.
  14. 14.Zoungas S, D'Alessio D, Pavo I, Bhatt DL, Buse JB, Del Prato S, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. Lancet Diabetes Endocrinol. 2026. PMID: 42114520.

Retatrutide for type 2 diabetes: TRIUMPH-2 Phase 3 results and Phase 2 evidence

Retatrutide is investigational and not FDA-approved. In TRIUMPH-2 (Lancet 2026, n=1,152, placebo-controlled), adults with obesity and T2D lost 18.8% of body weight on 12 mg vs 5.1% on placebo at 80 weeks. Lilly plans an FDA filing in Q1 2027.

18 min read

Retatrutide Dosage: TRIUMPH-1 Escalation Ladder + Clinical Evidence

Retatrutide (Eli Lilly LY3437943) is dosed weekly subcutaneously and escalated 2 mg to 4 mg to 6 mg to 9 mg to 12 mg in 4-week steps in TRIUMPH-1 — about 20 weeks to reach the max 12 mg dose. Pre-approval; final FDA-label dosing pending.

12 min read

FLOW Trial: Semaglutide Kidney Subgroup Detail (2026)

A deep dive into the FLOW trial secondary analyses: eGFR slope, cardiovascular and all-cause death, heart failure, and benefit across CKD severity, SGLT2i, and MRA subgroups.

13 min read

FLOW Trial Update: GLP-1 for CKD Stage 3-4 — The Evidence

Semaglutide reduced major kidney events by 24% in FLOW. We review the eGFR slope, the practical CKD prescribing protocol, the dialysis-imminent patient pathway, and how SURPASS-MULTI shapes tirzepatide's renal positioning.

12 min read

Retatrutide TRIUMPH Phase 3: Latest Pipeline Update

In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.

11 min read

Tirzepatide vs Retatrutide: GIP/GLP-1 vs Triple Agonist Evidence

Tirzepatide hits GLP-1 + GIP. Retatrutide adds glucagon for additional energy expenditure. We walk through the mechanism math, SURMOUNT-1 vs phase 3 TRIUMPH-1 cross-trial magnitude, and the trade-offs in HR + nausea + weight loss.

11 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo

starting price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →